C3.ai(US:AI) Globenewswireยท2025-10-10 19:32Core Points - A class action has been filed against C3.ai, Inc. on behalf of investors who acquired its securities between February 26, 2025, and August 8, 2025, due to allegations of misleading information regarding the CEO's health and its impact on business prospects [1][2] - The complaint highlights that C3.ai did not disclose how the CEO's health affected the company's ability to close deals and that management was ineffective in mitigating this impact, leading to concerns about the company's growth and profitability [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health, resulting in a stock price drop of over 25% from $22.13 to $16.47 [3] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by October 21, 2025, with the lead plaintiff representing other class members in the litigation [4] - Shareholders can remain absent class members and are not required to participate in the case to be eligible for recovery [4] Company Background - Robbins LLP, the firm handling the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5]